Hemolytic Anemia in a Glucose-6-Phosphate Dehydrogenase- Deficient Patient Receiving Hydroxychloroquine for COVID-19: A Case Report.
- Resource Type
- Article
- Authors
- Aguilar, Jorge; Averbukh, Yelena
- Source
- Permanente Journal. Summer2020, Vol. 24 Issue 4, p1-3. 3p.
- Subject
- *GLUCOSE-6-phosphate dehydrogenase deficiency
*HEMOLYTIC anemia
*HYDROXYCHLOROQUINE
*COVID-19
*GLUCOSE-6-phosphate dehydrogenase
*COVID-19 treatment
- Language
- ISSN
- 1552-5767
Introduction: The growing coronavirus disease 2019 (COVID- 19) pandemic initially led to widespread use of hydroxychloroquine sulfate as an off-label experimental treatment of this disease. Case Presentation: Acute hemolytic anemia developed in an African American man with COVID-19-related pneumonia and glucose-6-phosphate dehydrogenase (G6PD) deficiency who completed the standard 5-day experimental course of hydroxychloroquine. Although the trigger leading to our patient's hemolytic sequelae will never be known with certainty, his clinical course suggests that hydroxychloroquine use and/or COVID-19 infection may trigger hemolysis in susceptible patients with G6PD deficiency. Discussion: This case confirms recent findings that the potential risks of hydroxychloroquine therapy for COVID-19 may outweigh the benefits. [ABSTRACT FROM AUTHOR]